5-Fluorouracil (5-FU) has been used worldwide, and the correlation between its effects and thymidylate synthase (TS) expression has been reported in gastrointestinal malignancy. But the significance of TS expression for 5-FU-based chemotherapy has rarely been reported in non-small cell lung cancer (NSCLC). We investigated surgically resected specimens of 23 consecutive patients with previously untreated NSCLC. We used immunohistochemistry and western blot analysis with anti-TS polyclonal antibody to evaluate the existence of TS, and fluorodeoxyuridine-5′ ′ ′ ′-monophosphate (FdUMP) binding assay to evaluate the enzymic activity of TS. We found that 14 samples (60.9%) were positive immunohistochemically, and that the results of immunohistochemistry closely reflected the enzymic activity measured by FdUMP binding assay (ranging from 1.8 to 56.9 pmol/g protein). These results seem to support our experience that 5-FU and its derivatives are clinically significantly effective as a postoperative adjuvant chemotherapy against NSCLC.
Thymidylate synthase (TS) is an important target enzyme for 5-fluorouracil (5-FU), because it catalyzes an essential step in DNA synthesis: methylation of deoxyuridine-5′-monophosphate (dUMP) to deoxythymidine-5′-monophosphate (dTMP), which is an important substrate for DNA synthesis (Fig. 1) . When 5-FU is administered, it is converted to fluorodeoxyuridine-5′-monophosphate (FdUMP), which forms a ternary complex with TS and 5,10-methylene-tetrahydrofolate (m-THF). The ternary complex is an extremely stable, tight-binding covalent complex, and consequently FdUMP prevents methylation of dUMP by TS and inhibits DNA synthesis. 1) 5-FU and its derivatives have been used worldwide. The effectiveness of these drugs is well proven, and has been reported to correlate with the expression of TS in gastrointestinal malignancy. [2] [3] [4] [5] On the other hand, the significance of TS expression for 5-FU based chemotherapy has not been well investigated in non-small cell lung cancer (NSCLC), because 5-FU and its derivatives have not been thought to be effective against NSCLC in general. However, their administration as postoperative adjuvant chemotherapy for NSCLC can be effective. [6] [7] [8] We also previously reported that postoperative biochemical modulation (BCM) therapy using 5-FU and UFT (a combination drug of tegafur and uracil in a molar ratio of 1:4) combined with cisplatin (CDDP) is effective in advanced NSCLC. 9) These reports suggest that TS controls DNA synthesis in NSCLC cells as well, and that TS can be an important target enzyme for 5-FU in NSCLC. There is no report on the enzymic activity of TS in NSCLC tissue. This prompted us to investigate the expression of TS by immunohistochemistry and western blot analysis, as well as its enzymic activity by FdUMP binding assay in NSCLC tissue. (Table I) A total of 23 consecutive patients with previously untreated NSCLC were analyzed. They were treated surgically in Kyoto University Hospital from September 1995 to March 1996, and were diagnosed pathologically as NSCLC. There were 15 men and 8 women who ranged in age from 45 to 80 years (average 63.5). Informed consent was obtained from all the patients. Pathological tumor types were 17 adenocarcinomas, 3 squamous cell carcinomas, 1 large cell carcinoma, 1 adenosquamous cell carcinoma, and 1 atypical carcinoid. Fifteen of the 23 patients were diagnosed as having pathological stage I, 1 as stage II, 6 as stage IIIA, and 1 as stage IIIB. The pathological diagnosis was based on the WHO classification, 10) and the staging of all patients was made according to the International Staging System for Lung Cancer.
MATERIALS AND METHODS

Patients
11)
Tissue samples Tumor parts of the surgical specimen were immediately fixed in 10% formalin and stored at This work was presented in part at 8th World Conference on Lung Cancer, Dublin, Ireland, August, 1997. 4 To whom all correspondence should be addressed. Sections in which more than 10% of tumor cells were stained were judged to be TS-positive, and otherwise, TSnegative. Western blot analysis Tissue samples stored at −70°C were defrozen, homogenized with 200 mM Tris-HCl (pH 7.4, containing 20 mM 2-mercaptoethanol, 15 mM cytidine-5′-monophosphate (5′-CMP) and 100 mM NaF) and centrifuged at 105,000g for 60 min. The supernatant was loaded on 12.5% polyacrylamide gel (protein content was 25 µg/lane), and the proteins were electrically blotted to poly(vinylidene difluoride) (PVDF) membrane overnight at 4°C. TS expression was detected by applying anti-TS polyclonal antibody as a primary antibody (1 µg/ml) overnight at 4°C, and biotinylated goat anti-rabbit IgG as a 13) the supernatant was used for the determination of TS activity by addition of an excess of [6- 3 H]FdUMP. Protein content was determined using the Bio-Rad protein assay kit (Veementaal, The Netherlands). Statistical analysis Statistical analysis was performed with the 2-tailed unpaired t-test using the "SPSS for Windows" software system (SPSS, Chicago, IL).
RESULTS
Immunohistochemical staining
Fourteen samples (60.9%) out of the total of 23 were revealed to be TS-positive by immunohistochemistry. According to pathological types, 11 (64.7%) of 17 adenocarcinomas and one of three squamous cell carcinomas were TS-positive. One large cell carcinoma was TS-positive, and the adenosquamous cell carcinoma and atypical carcinoid were TS-negative (Table II) . Our antibody recognized not only malignant cells, but also endothelial cells, red blood cells and normal squamous cells. However, it was straightforward to judge the staining pattern of tumor cells by comparing the findings with those of HE staining (Fig. 2) . Western blot analysis TS protein was detected as a band of 37 kDa (Fig. 3) . The density of the band corresponded to the TS enzymic activity in FdUMP binding assay as mentioned below. FdUMP binding assay (Table III) treat gastrointestinal malignancy. TS expression in gastrointestinal malignancy has been extensively investigated, and it was reported that the presence and enzymic activity of TS were significantly correlated with sensitivity to 5-FU, post-chemotherapeutic clinical course and prognosis of the patients. [2] [3] [4] [5] In contrast, little information is available about TS and the clinical effects of 5-FU and its derivatives on NSCLC, because it has been generally believed that 5-FU and its derivatives are ineffective against NSCLC.
However, we reported in a prospective randomized study that postoperative oral administration of UFT (400 mg/body, for a year) for NSCLC had a significantly beneficial effect as compared with surgery alone. 6) Another Japanese group similarly reported that postoperative chemotherapy using CDDP (66 mg/m 2 ), adriamycin (26 mg/ m 2 ) and UFT (8 mg/kg/day, for 6 months) for NSCLC had a significantly beneficial effect. 7) We also reported that BCM therapy using 5-FU and UFT combined with CDDP was effective against advanced NSCLC.
8) Thus, we investigated TS expression and its enzymic activity in NSCLC tissue.
In this study, we demonstrated the presence of TS and its enzymic activity in NSCLC tissue by immunohistochemical staining, western blot analysis and FdUMP binding assay.
A problem in this study is that the results of immunohistochemistry were not significantly correlated with the results of FdUMP binding assay. There may be two reasons for this discrepancy. One possibility is problems with the immunohistochemical technique, that is to say, the formalin fixation and paraffin-embedding procedure may mask the antigenicity of TS. The other is the possibility of contamination with various amounts of normal tissue in the samples for FdUMP binding assay. TS expression was reported to exist in normal lung tissue and to be generally lower than in tumor tissue. 14, 15) We confirmed that some normal tissues were stained positively by our antibody. Considering that TS is abundant in normal cells with active DNA synthesis, it seems likely that contamination with normal tissue caused the discrepancy between immunohistochemistry and FdUMP binding assay. The problem might be resolved by evaluation of more samples, because rather few samples were investigated in this study. Moreover, normal tissue stained positively by immunohistochemistry was considered to reflect genuine TS protein in normal tissue except red blood cells, because TS protein was detected as a single band by western blotting in our study.
Thus, immunohistochemical evaluation of TS protein expression seems to be possible even in formalin-fixed tumor sections, reflecting the results of TS enzymic activity measurement by FdUMP binding assay, although some exceptions were found. Immunohistochemical staining of formalin-fixed tumor sections is very useful to investigate TS expression in numerous samples retrospectively. TS expression at the RNA level in gastrointestinal malignancy has been studied using the reverse transcription-polymerase chain reaction. 2, 5) Those investigators reported that patients with high TS mRNA expression had a lower response to 5-FU and its derivatives and a poorer prognosis. It was also reported that immunohistochemical TS protein expression and mRNA expression were highly correlated.
We found only one article that reported immunohistochemical TS expression in NSCLC, 16) in which the correlation between TS existence and sensitivity to postoperative chemotherapy using 5-FU, doxorubicin, and CDDP was studied. The results revealed that TS-positive patients had a significantly poor response to postoperative chemotherapy and a poor prognosis, as in the case of gastrointestinal malignancy. But in their study, the enzymic activity of TS in NSCLC was not investigated, and ours is the first report to determine the enzymic activity of TS in NSCLC by FdUMP binding assay.
5-FU and its derivatives require TS for effectiveness. Thus, 5-FU and its derivatives have the potential to be effective against NSCLC. But the number of samples was too small for us to decide how TS expression is related to drug sensitivity to 5-FU and its derivatives in NSCLC and how it influences the postoperative survival rate and disease-free survival. We should clarify the correlation between TS expression and drug sensitivity, postoperative survival rate and disease-free survival by investigating more samples in the future. We have already reported that p53 status is useful for predicting the efficacy of postoperative administration of UFT in completely resected NSCLC.
17) It would be of benefit to patients with NSCLC if the 5-FU based chemotherapeutic effect for each patient could be predicted from the TS information of a biopsy specimen, in conjunction with the p53 status.
We have demonstrated TS protein expression and its enzymic activity in NSCLC by immunohistochemistry and western blot analysis using anti-TS polyclonal antibody and FdUMP binding assay. This supports the idea that 5-FU and its derivatives may be clinically effective against NSCLC, for which these drugs had been thought to be of little value.
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